Friday, November 11, 2016

The values to follow the Paris stock Exchange at mid-session – Boursorama

LAFARGEHOLCIM, THE largest DECLINE OF the CAC 40 AT the MID-SESSION

LAFARGEHOLCIM, THE largest DECLINE OF the CAC 40 AT the MID-SESSION

PARIS (Reuters) – The values of the day Friday at the Paris Bourse, where the CAC 40 fell 0.82% to 4,494 state,02 percentage points to 12.40 pm, in a market, however, little active this holiday on November 11.

After an initial reaction to the positive markets in the victory of Donald Trump, investors are wondering now about the execution risks of the wide-ranging program of economic recovery of president-elect american.

* THE CONSTRUCTION SECTOR (-1,16%), which was affected Thursday a higher level of almost nine years due to the investment program of Trump in the infrastructure, is logically the costs of these doubts emerging. LAFARGEHOLCIM (-2,02% 51,79€) accuses the largest decrease in the CAC 40, putting an end to five consecutive sessions of gains.

* The session is marked, however, by a recovery in the european sector of public services (+1,33%), and by the good performance of the automotive (+1,56%) and property (+1.6 per cent):

* VEOLIA, which has sold nearly 17% since the beginning of the month, puts an end to this downward trend resumes and 3,41% to 17.14 euros, showing the largest increase in the CAC 40. SUEZ also won with 2.34 per cent to 13,125 euros.

* PEUGEOT wins at 2.16% to 13,975 euros, RENAULT 1,49% 73,78€. The land, UNIBAIL-RODAMCO takes of 2.43% and KLEPIERRE is 2.32%.

* SFR resists downward (+1.51 per cent to 23,51 eur) following the release Thursday evening of results marked by a beginning of recovery in France even if the telecom operators continue to lose subscribers in the mobile and fixed.

* INNATE PHARMA is gaining 2.49% to 13,18 euros after the announcement of a conference call next Monday at 14: 00 Paris time with the analysts to provide an update on its recent clinical data and, in particular, on its treatment antibody lirilumab and IPH4102.

(Jean-Michel Belot)


Values

LikeTweet

No comments:

Post a Comment